ArticleTranslational vision science & technology2025
Sustained Neurotrophic Factor Co-Treatment Enhances Donor and Host Retinal Ganglion Cell Survival in Mice.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-cell transcriptome of retinal myeloid cells in response to transplantation of human neurons reveals reversibility of microglial activation.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Purpose: Retinal ganglion cells (RGCs) lack regenerative capacity in mammals, and their degeneration in glaucoma leads to irreversible blindness. Autologous and allogeneic RGC replacement with stem cell-derived neurons is a promising strategy for vision restoration; however, low (<1%) donor cell survival in the diseased retina and optic nerve remains a major limitation. We aimed to improve initial donor RGC survival by supplementing transplants with slow-release neuroprotective factors. Methods: Mouse and human stem cell-derived RGCs were cultured and transplanted into mouse models of optic neuropathy with or without a slow-release formulation of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). Donor RGC differentiation, survival, and function were assessed in vitro using flow cytometry, multielectrode array recordings, and neurite outgrowth analysis. Donor RGC survival and host retinal function after transplantation and BDNF/GDNF co-treatment in mice were evaluated using retinal flat mounts and electroretinography. Results: Slow-release BDNF/GDNF significantly enhanced RGC differentiation, survival, and spontaneous neural activity in vitro. In vivo, co-treatment improved donor RGC transplantation outcomes by 2.7-fold for mouse RGCs and 15-fold for human RGCs in mice. Additionally, slow-release BDNF/GDNF preserved host RGC function, providing neuroprotection against injury-induced retinal dysfunction. Conclusions: Engineering the retinal microenvironment with slow-release neurotrophic factors significantly enhances both donor and host neuron survival, representing a promising approach for treating glaucoma and other optic neuropathies. Translational Relevance: This study demonstrates that sustained neurotrophic factor delivery can protect vision and improve retinal neuron transplantation outcomes, advancing the treatment of optic neuropathies at both mild and severe stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.